374 related articles for article (PubMed ID: 22870038)
1. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus.
Cen P; Amato RJ
Onco Targets Ther; 2012; 5():217-24. PubMed ID: 22870038
[TBL] [Abstract][Full Text] [Related]
2. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
[TBL] [Abstract][Full Text] [Related]
3. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
Liu E; Marincola P; Oberg K
Therap Adv Gastroenterol; 2013 Sep; 6(5):412-9. PubMed ID: 24003341
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Reidy-Lagunes D; Thornton R
Curr Oncol Rep; 2012 Jun; 14(3):249-56. PubMed ID: 22434313
[TBL] [Abstract][Full Text] [Related]
7. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
8. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
9. Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.
Yim KL
Cancer Manag Res; 2012; 4():207-14. PubMed ID: 22904642
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
11. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.
Fazio N; Carnaghi C; Buzzoni R; Valle JW; Herbst F; Ridolfi A; Strosberg J; Kulke MH; Pavel ME; Yao JC
Cancer; 2021 Aug; 127(15):2674-2682. PubMed ID: 33857327
[TBL] [Abstract][Full Text] [Related]
12. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic neuroendocrine tumors: a comprehensive review.
Zhou C; Zhang J; Zheng Y; Zhu Z
Int J Cancer; 2012 Sep; 131(5):1013-22. PubMed ID: 22437917
[TBL] [Abstract][Full Text] [Related]
14. Emerging use of everolimus in the treatment of neuroendocrine tumors.
Gajate P; Martínez-Sáez O; Alonso-Gordoa T; Grande E
Cancer Manag Res; 2017; 9():215-224. PubMed ID: 28684922
[TBL] [Abstract][Full Text] [Related]
15. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response.
Alors-Pérez E; Pedraza-Arevalo S; Blázquez-Encinas R; García-Vioque V; Agraz-Doblas A; Yubero-Serrano EM; Sánchez-Frías ME; Serrano-Blanch R; Gálvez-Moreno MÁ; Gracia-Navarro F; Gahete MD; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102090. PubMed ID: 38187140
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumors: entering a new era.
Oberstein PE; Remotti H; Saif MW; Libutti SK
JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in the management of metastatic neuroendocrine tumours.
Chan DL; Segelov E; Singh S
Therap Adv Gastroenterol; 2017 Jan; 10(1):132-141. PubMed ID: 28286565
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
19. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.
Coppin C
Biologics; 2010 May; 4():91-101. PubMed ID: 20531964
[TBL] [Abstract][Full Text] [Related]
20. Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
D'Onofrio M; Cingarlini S; Ortolani S; Crosara S; DE Robertis R; Vallerio P; Grego E; Ciaravino V; Ruzzenente A; Landoni L; Scarpa A; Bassi C; Tortora G
Anticancer Res; 2017 Mar; 37(3):1305-1311. PubMed ID: 28314296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]